title: [Polymorphism of the biotransformation gene--cytochrome-450 2C9 in the patients with tuberculosis].
abstract: The goal of this work was to study cytochrome-450 (CYP) 2C9 (CYP2C9) gene polymorphism in patients with tuberculosis (TB) and its meaning for development, progress, and outcome of TB, for the pharmacokinetics of the antituberculosis antibiotic rifampicin on the basis of the southern region of Ukraine. Among the TB patients it was 24.9% less than in carriers of the genotype *1/*1 and than in healthy donors. At the same time, it was 25.0% less than in carriers of the genotypes *1/*2, *1/*3. In the TB patientswith the genotype *2/*3, *3/*3 the level of rifampicin in blood was the lowest. At the beginning of the treatment in carriers of genotype *1/*1 the pulmonary destruction was observed 2.5 times more often than in *1/*2, *1/*3 genotype. According to the cultural method, the carriers of *1/*1 more frequently became smear-negative than the carriers of *1/*2, *1/*3 genotype.
authors.forename: P B
authors.initials: PB
authors.lastname: Antonenko
authors.forename: V I
authors.initials: VI
authors.lastname: Kresyun
mesh_terms: D000328:Adult; D000368:Aged; D000904:Antibiotics, Antitubercular / Q000097:blood / Q000627:therapeutic use; D001189:Aryl Hydrocarbon Hydroxylases / Q000235:genetics*; D065729:Cytochrome P-450 CYP2C9; D005260:Female; D005838:Genotype; D006579:Heterozygote; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D012293:Rifampin / Q000097:blood / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics*
chemical_list: D000904:Antibiotics, Antitubercular; C450260:CYP2C9 protein, human; D065729:Cytochrome P-450 CYP2C9; D001189:Aryl Hydrocarbon Hydroxylases; D012293:Rifampin